PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis

The PI3K pathway is frequently activated in cancer; therefore, considerable effort is focused on identifying compounds that can inhibit specific pathway components, particularly the hallmark oncogene PIK3CA. Although targeted inhibition of a cancer survival gene holds significant promise, there are concerns that drug resistance may emerge within the cancerous cells, thus limiting clinical efficacy. Using genetically defined human mammary epithelial cells, we evolved resistance to the PI3K/mammalian target of rapamycin (mTOR) inhibitor BEZ235, and by genome-wide copy number analyses, we identified MYC and eIF4E amplification within the resistant cells. Importantly, either MYC or eukaryotic translation initiation factor 4E (eIF4E) was required to bypass pharmacological PI3K/mTOR inhibition in resistant cells. Furthermore, these cells displayed elevated 5′ cap-dependent protein translation. Collectively, these findings suggest that analysis of drivers of protein translation could facilitate the identification of cancer lesions that confer resistance to PI3K pathway-targeted drugs.

[1]  Hilla Peretz,et al.  Ju n 20 03 Schrödinger ’ s Cat : The rules of engagement , 2003 .

[2]  L. Cantley,et al.  Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate , 1988, Nature.

[3]  N. Sonenberg,et al.  Translation initiation factors induce DNA synthesis and transform NIH 3T3 cells. , 1990, The New biologist.

[4]  N. Sonenberg,et al.  The mRNA 5' cap-binding protein, eIF-4E, cooperates with v-myc or E1A in the transformation of primary rodent fibroblasts , 1992, Molecular and cellular biology.

[5]  E. Shaulian,et al.  Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding , 1992, Molecular and cellular biology.

[6]  K. Isselbacher,et al.  Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-2 alpha in response to growth induction by c-myc. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[7]  N. Sonenberg,et al.  Elevated levels of cyclin D1 protein in response to increased expression of eukaryotic initiation factor 4E , 1993, Molecular and cellular biology.

[8]  L. Shantz,et al.  Overproduction of ornithine decarboxylase caused by relief of translational repression is associated with neoplastic transformation. , 1994, Cancer research.

[9]  An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc. , 1996, Molecular and cellular biology.

[10]  F. Waldman,et al.  Patterns of epidermal growth factor receptor amplification in malignant gliomas. , 1996, The American journal of pathology.

[11]  R. Weinberg,et al.  hEST2, the Putative Human Telomerase Catalytic Subunit Gene, Is Up-Regulated in Tumor Cells and during Immortalization , 1997, Cell.

[12]  T. Kiyono,et al.  Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells , 1998, Nature.

[13]  D. Prober,et al.  Drosophila myc Regulates Cellular Growth during Development , 1999, Cell.

[14]  J. Sedivy,et al.  Mysterious liaisons: the relationship between c-Myc and the cell cycle , 1999, Oncogene.

[15]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[16]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[17]  P. J. Welch,et al.  Involvement of Proteasome α-Subunit PSMA7 in Hepatitis C Virus Internal Ribosome Entry Site-Mediated Translation , 2001, Molecular and Cellular Biology.

[18]  J. Kuriyan,et al.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.

[19]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[20]  Lewis C Cantley,et al.  The phosphoinositide 3-kinase pathway. , 2002, Science.

[21]  John D. Watson,et al.  Identifying Genes Regulated in a Myc-dependent Manner* , 2002, The Journal of Biological Chemistry.

[22]  J. Blenis,et al.  Coordinate regulation of translation by the PI 3-kinase and mTOR pathways. , 2002, Advances in cancer research.

[23]  W. Hahn,et al.  Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. , 2003, Cancer cell.

[24]  G. Daley,et al.  Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL , 2003, Cell.

[25]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[26]  Ming Tan,et al.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.

[27]  P. Pandolfi,et al.  The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis , 2004, Nature Medicine.

[28]  E. Schmidt.  The role of c-myc in regulation of translation initiation , 2004, Oncogene.

[29]  M. Loda,et al.  The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Carlo Rago,et al.  Mutant PIK3CA promotes cell growth and invasion of human cancer cells. , 2005, Cancer cell.

[31]  Carlo Rago,et al.  Mutant PIK 3 CA promotes cell growth and invasion of human cancer cells , 2005 .

[32]  M. Loda,et al.  The oncogenic properties of mutant p110α and p110β phosphatidylinositol 3-kinases in human mammary epithelial cells , 2005 .

[33]  C. Meschonat,et al.  Detection of eIF4E gene amplification in breast cancer by competitive PCR , 1998, Annals of Surgical Oncology.

[34]  L. Terracciano,et al.  An update on molecular genetics of gastrointestinal stromal tumours , 2006, Journal of Clinical Pathology.

[35]  M. Maemondo,et al.  Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[37]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[38]  G. Mills,et al.  A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. , 2007, Cancer cell.

[39]  M. Moasser.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis , 2007, Oncogene.

[40]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[41]  Alona Muzikansky,et al.  First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Olufunmilayo I Olopade,et al.  MYC in breast tumor progression , 2008, Expert review of anticancer therapy.

[43]  R. Parsons,et al.  The role of PTEN signaling perturbations in cancer and in targeted therapy , 2008, Oncogene.

[44]  Eli R. Zunder,et al.  Discovery of Drug-resistant and Drug-sensitizing Mutations in the Oncogenic Pi3k Isoform P110a , 2022 .

[45]  J. Baselga,et al.  NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. , 2008, Cancer research.

[46]  L. Cantley,et al.  PI3K pathway alterations in cancer: variations on a theme , 2008, Oncogene.

[47]  Violeta Serra,et al.  NVP-BEZ 235 , a Dual PI 3 K / mTOR Inhibitor , Prevents PI 3 K Signaling and Inhibits the Growth of Cancer Cells with Activating PI 3 K Mutations , 2008 .

[48]  M. Meyerson,et al.  The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP , 2008, Proceedings of the National Academy of Sciences.

[49]  J. Blenis,et al.  Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1 , 2008, Proceedings of the National Academy of Sciences.

[50]  Gary Box,et al.  The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer . , 2008, Journal of medicinal chemistry.

[51]  C. Chresta,et al.  Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR) , 2009, The Biochemical journal.

[52]  M. Sliwkowski,et al.  Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. , 2009, Cancer cell.

[53]  Dexin Kong,et al.  Advances in development of phosphatidylinositol 3-kinase inhibitors. , 2009, Current medicinal chemistry.

[54]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[55]  Clifford A. Meyer,et al.  MYC regulation of a “poor-prognosis” metastatic cancer cell state , 2010, Proceedings of the National Academy of Sciences.

[56]  Luca Toschi,et al.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. , 2010, Cancer cell.